Preventing HIV-Related Comorbidities in Adolescents



Professor of Pediatric and Adult Infectious Diseases
Director, Pediatric Adolescent HIV/AIDS Program and
Accessing Care Early Clinic
Johns Hopkins School of Medicine
Baltimore, Maryland


Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years

Dr Agwu has served on the scientific advisory boards for Gilead Sciences, Inc., and Merck & Co, Inc. (Updated 9/29/21)

Learning Objectives


At the end of this presentations, learners will be able to:

- Review the epidemiology of adolescents living with HIV
- Describe risk factors for developing comorbidities over the life course among adolescents with HIV
- Discuss opportunities to prevent comorbidities and optimize outcomes






Age Distribution of Persons Living with Diagnosed Perinatally Acquired HIV Infection, Year-end 2017—United States and 6 Dependent Areas (N = 11,924)




Many AYA born with HIV are thriving......





Diagnoses of HIV Infection among Adults and Adolescents by Age at Diagnosis, 2018—United States




(CDC)

 $\it Note.$ Data for the year 2018 are considered preliminary and based on 6 months reporting delay. Slide 7 of 40



Adolescents and Young Adults Aged 13–24 Years Living with Diagnosed HIV Infection by Sex and Transmission Category, Year-end 2017—United States and 6 Dependent Areas



Note. Data have been statistically adjusted to account for missing transmission category. "Other" transmission category not displayed as it comprises 1% or less cases.

Slide 8 of 40


Yusuf & Agwu. Expert Review of Anti-Infective Therapy.

^a Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

b Includes hemophilia, blood transfusion, and risk factor not reported or not identified.



Adolescents and Young Adults Aged 13–24 Years Living with Diagnosed HIV Infection, by Sex and Race/Ethnicity, Year-end 2017—United States and 6 Dependent Areas






^b Hispanics/Latinos can be of any race.

Slide 9 of 40

CDC



Persons Living with Diagnosed or Undiagnosed HIV Infection HIV Care Continuum Outcomes, by Age, 2018—United States






Note. Receipt of medical care was defined as ≥1 test (CD4 or VL) in 2018. Retained in continuous medical care was defined as ≥2 tests (CD4 or VL) ≥3 months apart in 2018. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2018.

Slide 10 of 40









Slide 11 of 40





Life course perspective for adolescents with HIV

	2 nd Decade
	10-19 years
	AK
Life events	School
	Trade School/College
	Employment
	Parent/guardian loss
Self-management	Parental/caregiver
	involvement wanes
Disclosure	Disclosure (to self)
	Disclosure to others
Stigma	Internal and external stigma








Life course perspective for adolescents with HIV

	2 nd Decade	3 rd Decade	4 th Decade	5 th Decade	≥6 th Decade
	10-19 years	20-29 years	30-39 years	40-49 years	≥50 years
	* R	MAN	THE STATE OF THE S		
		Treatment and Treatmer	nt-related Factors		
Antiretroviral treatment	Simple regimens* Increased responsibility of ART	Simple regimen Increased complex regimens due to development of resistance Full responsibility of ART	Simple regimen Increased complex regime Full responsiblilty of ART	ens due to development o	of resistance

Slide 13 of 40 Yusuf and Agwu 2021







How will adolescents with HIV infection be impacted?





	Leading Cause of Death in the United States for Select Age Groups (2019) Data Courtesy of CDC									
Rank	10-14	15-24	25-34	35-44	45-54	55-64	All Ages			
1	Unintentional Injury 778	Unintentional Injury 11,755	Unintentional Injury 24,516	Unintentional Injury 24,070	Malignant Neoplasms 35,587	Malignant Neoplasms 111,765	Heart Disease 659,041			
2	Suicide 534	Suicide 5,954	Suicide 8,059	Malignant Neoplasms 10,695	Heart Disease 31,138	Heart Disease 80,837	Malignant Neoplasms 599,601			
3	Malignant Neoplasms 404	Homicide 4,774	Homicide 5,341	Heart Disease 10,499	Unintentional Injury 23,359	Unintentional Injury 24,892	Unintentional Injury 173,040			
4	Homicide 191	Malignant Neoplasms 1,388	Malignant Neoplasms 3,577	Suicide 7,525	Liver Disease 8,098	CLRD 18,743	CLRD 156,979			
5	Congenital Anomalies 189	Heart Disease 872	Heart Disease 3,495	Homicide 3,446	Suicide 8,012	Diabetes Mellitus 15,508	Cerebro- vascular 150,005			
6	Heart Disease 87	Congenital Anomalies 390	Liver Disease 1,112	Liver Disease 3,417	Diabetes Mellitus 6,348	Liver Disease 14,385	Alzheimer's Disease 121,499			
7	CLRD 81	Diabetes Mellitus 248	Diabetes Mellitus 887	Diabetes Mellitus 2,228	Cerebro- vascular 5,153	Cerebro- vascular 12,931	Diabetes Mellitus 87,647			
8	Influenza & Pneumonia 71	Influenza & Pneumonia 175	Cerebro- vascular 585	Cerebro- vascular 1,741	CLRD 3,592	Suicide 8,238	Nephritis 51,565			
9	Cerebro- vascular 48	CLRD 168	Complicated Pregnancy 532	Influenza & Pneumonia 951	Nephritis 2,269	Nephritis 5,857	Influenza & Pneumonia 49,783			
10	Benign Neoplasms 35	Cerebro- vascular 158	HIV 486	Septicemia 812	Septicemia 2,176	Septicemia 5,672	Suicide 47,511			


CLRD: Chronic Lower Respiratory Disease

Note: Suicide is not among the ten leading causes of death among children in the 0-9 year age group nor in adults in the age group 65 years and older.





Percentage of adults in the U.S. with diabetes as of 2016, by age and ethnicity






Note(s): United States; January 2 to December 30, 2016; 18 years and older; 177,192 respondents; Full or part time workers Further information regarding this statistic can be found on <u>page 8</u>. **Source(s):** Gallup (Gallup-Sharecare Well-Being Index); Sharecare; <u>ID 790778</u>

statista ✓ Geffner ME. Horm Res Paediatr 2011; 76: 386-91










Rates of Adolescents Aged 13-19 Years Living with Diagnosed HIV Infection **Year-end 2017—United States and 6 Dependent Areas**



American Samoa 0.0 Guam 5.0 Northern Mariana Islands 0.0 Puerto Rico 14.6 Republic of Palau 0.0 U.S. Virgin Islands 34.3




Note. Data are based on address of residence as of December 31, 2017 (i.e., most recent known address).

Slide 18 of 40





Prevalence of hypertension among adults in the U.S. in 2017 and 2018, by age and gender




Slide 19 of 40





ART?




Slide 20 of 40





23 year old with HIV and acute chest pain



Slide 21 of 40 Griffith OFID 2018





CVD Data for Youth with HIV


- Studies of children and youths in non-HIV disease states (diabetes, obesity) link arterial stiffness and
 - thickness to hypertension & increased left ventricular mass
- Limited data on youth with perinatal infection
 - ↑ arterial thickness (carotid intimal medial thickness) in HIV+ vs. HIV-
 - \uparrow arterial stiffness (pulse wave velocity) & \downarrow flow-mediated dilatation in HIV+ vs. HIV-
 - ↑ inflammatory markers in HIV+ vs. HIV- → associated with arterial thickness, stiffness, and flow-mediated dilatation
 - ↑ inflammatory markers despite longstanding virologic suppression
 - AYA with HIV have higher markers of cardiopulmonary dysfunction
 - Up to 28% show evidence of early cardiovascular dysfunction
 - Biomarkers of cardiomyocyte stress and injury (high sensitivity cardiac troponin-T [hs-cTnT] and N-terminal-probrain natriuretic peptide [NT- proBNP]) are elevated compared to uninfected adolescents after adjusting for adherence to ART,
 - Inflammation associated with poorer left ventricular function and increased stress in the ventricular walls







Long-term morbidity of HIV +/- ART






Griffith D et al. OFID 2017; Hazra R et al.; Izbudak, Agwu J Neurorad 2013;, Venkataramani 2012; Eckard et al Curr HIV/AIDS 2016; Neilan et al JAMA Peds 2017







Mental health in adults born with HIV



Slide 25 of 40

Phillips Pediatrics 2016; Malee AIDS Care 2011; Scharko AIDS Care 2006; Earnshaw AIDS & Behavior 2018; Well Project; Winston A et al Lancet HIV 2020





Sexual and reproductive health for adults born with HIV

	2 nd Decade	3 rd Decade	4 th Decade	5 th Decade	≥6 th Decade
	10-19 years	20-29 years	30-39 years	40-49 years	≥50 years
	*	MAN	***		
		Canada and Danas de			
		Sexual and Reprodu			
Sex/reproductive	Sexual and gender identify	Secondary Prevention	Secondary	Secondary Pr	
	evolving; Sexual activity	Child bearing	Prevention	Risk redu	iction
	often commences	Risk reduction	Child bearing		
	Risk reduction		Risk reduction		





STI Rates among adolescents

Rates of chlamydia, gonorrhea, and primary & secondary syphilis ↑ for both sexes in 15–24 year olds (2013-2017)

Chlamydia: highest among women; males ↑ 29%, females ↑ 9%


Gonorrhea: males ↑ 52%, females ↑ 24%

Reasons include: incidence, screening, extragenital screening

HIV positive adolescents:

- Perinatally acquired: ↑ likelihood to use condoms (60% use condoms inconsistently); 30% have >1 concurrent partner
- Non-perinatally acquired: continued sexual activity, inconsistent condom use
- Pregnancy desires unchanged


Figure 5. Chlamydia — Rates of Reported Cases by Age Group and Sex, United States, 2017








Comorbidities and Sequelae Resulting from STIs



Unemo et al. Lancet ID 2017. 17(8): E235-79












Tobacco use among adolescents

- YHIV: up to 40% report tobacco use
- 20% report daily/almost daily tobacco use




Gamarel AIDS Behav 2018; Nasim et al. Nicotine & Tobacco Research 2016; https://www.cdc.gov/tobacco/data_statistics/fact_sheets/youth_data/tobacco_use/index.htm





Obesity

- 21% of 12-19 year olds are obese
 - Hispanic (26%)
 - non-Hispanic Black (24%)
 - non-Hispanic White (16%)
- Obesity among U.S. youth with HIV
 - Overweight/obese (49%)
 - YHIV 10% higher trunk to fat ratio than HEU




2019





Weight again among adolescents with HIV on INSTIs







Treatment Developing ideal treatment dosing regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	Treatment Developing ideal treatment dosing regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Long ideal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies		2 nd Decade	3 rd Decade	4 th Decade	5 th Decade	≥6 th Decade
Treatment Developing ideal treatment dosing Minimizing polypharmacy, optimizing ART, minimizing drug interactions regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	Treatment Developing ideal treatment dosing Minimizing polypharmacy, optimizing ART, minimizing drug interactions regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions						
Treatment Developing ideal treatment dosing Minimizing polypharmacy, optimizing ART, minimizing drug interactions regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	Treatment Developing ideal treatment dosing Minimizing polypharmacy, optimizing ART, minimizing drug interactions regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions		AK				
treatment dosing regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	treatment dosing regimens and formulations Long acting antiretroviral therapy, non-ART treatment strategies, HIV cure Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions			Future Clinical and Re	search Focus		
Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	Comorbidities Longitudinal studies on HIV comorbidities and early biomarkers of organ/systemic dysfunction, prevention strategies Impact of customized mental health screening and interventions	Treatment	treatment dosing regimens and	Minimizin	g polypharmacy, optimizi	ng ART, minimizing drug inte	ractions
Impact of customized mental health screening and interventions	Impact of customized mental health screening and interventions		Long acting antiretroviral the	rapy, non-ART treatment strat	egies, HIV cure		
		Comorbidities	Longitudinal studies on HIV	comorbidities and early bioma	rkers of organ/systemic	dysfunction, prevention strat	egies
Minimizing cognitive dysfunction	Minimizing cognitive dysfunction		Impact of customized menta	I health screening and interve	ntions		
William izing cognitive dystanction							





What can you do?

- Take a good history
- Assess risk factors
 - Tobacco
 - Substances
 - Sex
 - Activities
 - Helmets, firearms
- Detailed family history
- Physical examination

Rank	10-14	15-24	25-34	35-44	45-54	55-64	All Ages
1	Unintentional Injury 778	Unintentional Injury 11,755	Unintentional Injury 24,516	Unintentional Injury 24,070	Malignant Neoplasms 35,587	Malignant Neoplasms 111,765	Heart Disease 659,041
2	Suicide 534	Suicide 5,954	Suicide 8,059	Malignant Neoplasms 10,695	Heart Disease 31,138	Heart Disease 80,837	Malignant Neoplasms 599,601
3	Malignant Neoplasms 404	Homicide 4,774	Homicide 5,341	Heart Disease 10,499	Unintentional Injury 23,359	Unintentional Injury 24,892	Unintentional Injury 173,040
4	Homicide 191	Malignant Neoplasms 1,388	Malignant Neoplasms 3,577	Suicide 7,525	Liver Disease 8,098	CLRD 18,743	CLRD 156,979
5	Congenital Anomalies 189	Heart Disease 872	Heart Disease 3,495	Homicide 3,446	Suicide 8,012	Diabetes Mellitus 15,508	Cerebro- vascular 150,005
6	Heart Disease 87	Congenital Anomalies 390	Liver Disease 1,112	Liver Disease 3,417	Diabetes Mellitus 6,348	Liver Disease 14,385	Alzheimer's Disease 121,499
7	CLRD 81	Diabetes Mellitus 248	Diabetes Mellitus 887	Diabetes Mellitus 2,228	Cerebro- vascular 5,153	Cerebro- vascular 12,931	Diabetes Mellitus 87,647
8	Influenza & Pneumonia 71	Influenza & Pneumonia 175	Cerebro- vascular 585	Cerebro- vascular 1,741	CLRD 3,592	Suicide 8,238	Nephritis 51,565
9	Cerebro- vascular 48	CLRD 168	Complicated Pregnancy 532	Influenza & Pneumonia 951	Nephritis 2,269	Nephritis 5,857	Influenza & Pneumonia 49,783
10	Benign Neoplasms 35	Cerebro- vascular 158	HIV 486	Septicemia 812	Septicemia 2,176	Septicemia 5,672	Suicide 47,511

CLRD: Chronic Lower Respiratory Disease

Note: Suicide is not among the ten leading causes of death among children in the 0-9 year age group nor in adults in the age group 65 years and older.





What can you do?

- Education (patient and staff)
- Counseling
 - Nutrition
 - Exercise
 - Tob/nicotine (cigarettes, vape, cigarillos, e-cigs)
 - Substance, ETOH use
 - Sex
 - Etc
- Screening: BP, lipids (fasting/non- fasting), glucose, weight



Slide 36 of 40 USPSTF





Risk calculators for adolescents?

- ASCVD Heart Risk Calculator (age 40-79)
- If you know your lipids information and you are <60, the Framingham Heart Study General Cardiovascular Disease 30-Year Lipid-Based Risk Score Calculator is used. FOR AGES 30-79
- If you don't know your lipids information and you are <60, the Framingham Heart Study General Cardiovascular Disease 30-Year BMI-Based Risk Score Calculator is used. FOR AGES 30-79
- If you know your lipids information and you are ≥60 or older, the ACC/AHA Pooled Cohort Equations CV Risk Calculator is used.
- If you don't know your lipids information and you ≥ 60 or older, the Framingham Heart Study Cardiovascular Disease 10-Year BMI-Based Risk Score Calculator is used.

Heart Disease Risk Calculator

Heart Disease Risk Calculator Use the heart disease 18 years risk calculator to find out your risk of Male Female Gender cardiovascular disease. Height Weight lbs. Race Switch to Metric Units This heart disease risk assessment is most accurate for people between ages 20 and 74. For people younger than 20 or older than 74, the presence of two or more cardiovascular risk factors suggests a higher risk of cardiovascular disease. If you're in that category, you should seek additional evaluation and treatment advice from your doctor. Continue)

http://www.cvriskcalculator.com/; https://www.mayoclinichealthsystem.org/locations/menomonie/services-and-slide 37 of 40 treatments/cardiology/heart-disease-risk-calculator






What can you do?

Actions:

- Smoking cessation
- Lifestyle modification
- Treatment
 - HTN (<130/80 goal) or <90th percentile
 - Hyperlipidemia: ?? (benefit for older youth with clear abnormal)
- Weight loss
- hyperlipidemia
- Substance use treatment
- STI counseling, screening, and treatment; family planning
- Immunizations



Slide 38 of 40 USPSTF





Conclusion

- Adolescents with HIV (perinatally or non-perinatally acquired) are surviving into adulthood
- Providers must be aware of potential comorbidities that may arise in adolescence
- Critically important to screen for and address comorbidities with prevention and early treatment.

